BHVN vs TVTX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
TVTX Captures Institutional Edge (2โ2 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Travere Therapeutics, Inc. Common Stock (TVTX) driven by superior Valuation, Options & Structure while BHVN counters with relative strength in Growth & Margin, Momentum & Technical. Fundamentally, BHVN trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus TVTX at 9.3x Forward P/E and -3.1% operating margin (+36.2% YoY). In options structure, BHVN sits in CONSOLIDATION (18th %ile IV; Dealer Gamma Walls on Pro) against TVTX sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | BHVN | TVTX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.1B | $4.9B | Larger Scale | TVTX |
| Trailing P/E Ratio Valuation | N/M | 25.8x | Lower Multiple | TVTX |
| Forward P/E Ratio Valuation | N/M | 9.3x | Lower Multiple | TVTX |
| Revenue Growth (YoY) Growth | +0.0% | +36.2% | Higher Growth | TVTX |
| Operating Margin (TTM) Profitability | 0.0% | -3.1% | Higher Margin | BHVN |
| Net Profit Margin Profitability | 0.0% | -18.7% | Higher Margin | BHVN |
| Return on Equity (ROE) Capital Efficiency | -799.5% | -321.2% | Higher ROE | TVTX |
| 52-Week Range Position Momentum | 59% ($8โ$18) | 59% ($23โ$69) | Stronger Trend | TVTX |
| Beta / 30D Volatility Risk Regime | 1.41ฮฒ ยท 111% Vol | 1.39ฮฒ ยท 44% Vol | Lower Realized Risk | TVTX |
| Unified Institutional Score Composite Signal | 42.1 / 100 (HOLD) | 60.2 / 100 (BUY) | Higher Composite | TVTX |